The phenotypes of mitochondrial diseases caused by mutations in mitochondrial DNA (mtDNA) have been proposed to be strictly regulated by the proportion of wild-type and pathogenically mutated mtDNAs. More specifically, it is thought that the onset of the disease phenotype occurs when cells cannot maintain the proper mitochondrial function because of an over-abundance of pathological mtDNA.
Introduction
Mitochondria play several essential roles in cell functions, and the accumulation of mitochondrial DNA (mtDNA) with pathogenic mutations causes mitochondrial diseases, including mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS); myoclonus epilepsy with ragged red fibers (MERRF);
Kearns-Sayre syndrome (KSS); and chronic progressive external ophthalmoplegia (CPEO) [1, 2] .
One general feature of mitochondrial diseases is that at least two types (wild-type and mutated) of mtDNA exist in a single cell, which is a genetic status called heteroplasmy.
Several mouse models have been generated to study human mitochondrial diseases, including heteroplasmic mtDNA genetics. These mice possess mtDNAs derived from two strains [3, 4] containing either point-mutated mtDNA [5, 6] or mtDNA that has a large deletion [7] . These mice have been used to study mtDNA transmission, pathogenic mechanisms, and the development of an effective therapies for diseases. Effective treatment procedures for diseases have not yet been established, although several attempts have been reported, including a study in which one type of mtDNA (presumably pathogenic) was specifically digested by a mitochondrial-targeted restriction enzyme [8] . However, this treatment is difficult to apply practically to medical care because the restriction sites specific to the pathogenic mutant on the mtDNA are rare.
Mitochondrial diseases are caused by the accumulation of mtDNA with pathogenic mutations in single cells followed by the reduction of mitochondrial respiration activity.
Interestingly, this reduction of activity does not simply and linearly correlate with the proportion of mutated mtDNA but is caused only when the proportion of the mutated mtDNA exceeds a certain threshold level [7, 9, 10] . This phenomenon is thought to be caused by the occurrence of inter-mitochondrial complementation through the mixing of genetic contents [10] due to mitochondrial dynamics, such as fusion, fission and transportation [11] that makes mitochondria function as a single cellular unit [12] . The accumulation of mutated mtDNA causes a decrease in wild-type mtDNA, which results in a reduction of genetic factors and defects in respiratory activity.
The depletion of mtDNA copy number in humans [13] and mice [14] has caused severe diseases, such as mtDNA depletion syndrome (MDS). Furthermore, the down-regulation of mtDNA replication or transcription by knockout [15] or knockdown [16] of the Tfam gene, which encodes the mtDNA binding protein, results in decreased respiratory activity. These data suggest that an appropriate copy number of normal mtDNA is essential for the maintenance of mitochondrial function and that cells carrying mutated mtDNA may be rescued by the increase of wild-type mtDNA sufficient to supply normal rRNAs, tRNAs and proteins.
Based on this view, we generated transgenic mice that over-express Tfam to increase the total mtDNA copy number [17, 18] , and we mated these mice to the mitochondrial diseases model mice (mito-mice) with mutant mtDNA carrying a deletion of 4696 bp (#mtDNA) [7] . The increase in total mtDNA copy number due to the over-expression of Tfam in the mito-mice improved the severe symptoms of mitochondrial disease exhibited by the mito-mice, resulting in a prolonged life span. From this study, we propose a novel therapeutic treatment for mitochondrial diseases. We propose that an increase in the absolute copy number of healthy mtDNA restores the normal mitochondrial function even under conditions where the proportion of pathogenic mtDNA is unchanged.
Mouse strains
The C57BL/6J (CLEA Japan), mito-mouse [7] and Tfam/EGFP-Tg strains were used in this research. The Institutional Animal Experiment Committee approved all of the animal experiments.
Estimation of mtDNA copy number by comparative real-time PCR
Comparative real-time PCR for estimating the copy number of mtDNA in the tissues of mito-mice and Tg-mito-mice was performed using a QuantiTect SYBR Green PCR Kit (Qiagen) with Gapdh as the control for the nuclear genome copy number.
The following primers were used: 5$-AAC TCA AAG GAC TTG GCG GTA CTT TAT ATC-3$ and 5$-GAT GGC GGT ATA TAG GCT GAA TTA GCA AGA G-3$ to amplify the region common in both the wild-type and the deleted mtDNA, and 5$-AAC GAC CCC TTC ATT GAC-3$ and 5$-TCC ACG ACA TAC TCA GCA C-3$ for Gapdh [19] .
The total DNA samples purified from the tissues were diluted to a concentration of 100 pg/µl -1000 pg/µl and amplified using an ABI Prism 7900 (Applied Biosystems).
The thermal cycling conditions were as follows: 50°C for 2 min; 95°C for 15 min; and 40 cycles of 95°C for 20 sec followed by 60°C for 60 sec.
Estimation of #mtDNA proportions by real-time PCR
Real-time PCR was used to estimate the proportions of #mtDNA, as previously described [20] .
Northern blot for mitochondrial tRNA
Total RNA was purified from homogenized tissue samples using ISOGEN (NIPPON GENE), and Northern blots were then carried out as previously described [21, 22] . The DNA sequences for the specific probes were as follows: 5'-ATG TTT TTA AAC ATG GAA GCA TGA A-3' for tRNA Ser(AGY) and 5'-GTC TCC CAT CCA AGT ACT AAC CAA G-3' for 5S rRNA.
BUN measurement
were measured using a Urea N B kit (Wako Pure Chemical) as previously described [23] .
Histochemical analyses of COX and SDH activity
Histochemical analyses of cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) activity were carried out as previously described [7, 10] . Hearts and kidneys were excised from the animals, and 10-µm cryosections from the tissues were stained for COX and SDH activity.
Single-fiber PCR analysis
Two serial 10-%m cryosections of heart muscle were used for single-fiber PCR.
One of the sections was stained for COX and SDH activity, and the COX-positive fibers were selected for PCR analysis. Another section was used for the dissection of the cytoplasm corresponding to the COX-positive fibers with an LMD6000 (Leica). The total DNA was extracted from dissected samples and used directly for PCR analysis as previously described [24] . The PCR conditions were also carried out as described above.
Results

Tfam/EGFP over-expression increased the amount of mtDNA
We generated a transgenic (Tg) mouse strain that over-expressed the mtDNA binding protein, TFAM, combined with EGFP (C57BL/6J-Tg(CAG-Tfam/EGFP)38Rin,
Tfam/EGFP-Tg) (Fig. S1a) . Compared with wild-type mice, the Tfam/EGFP-Tg mice displayed 9.10-fold (heart) and 5.67-fold (kidney) levels of total Tfam mRNA, but the same levels of endogenous Tfam (Fig. S1b) . The TFAM/EGFP protein expression level was measured by Western blot using an antibody specific to GFP. The left ventricle, kidney and pancreas had a relatively higher expression of TFAM/EGFP, but the spleen and stomach had low levels. In Western blot analysis using cell fractionation of the heart and kidney, EGFP was detected in the mitochondrial fraction ( Fig. S1c) , and it was also found to be localized to the mitochondrial matrix using immunoelectron microscopy in the Tfam/EGFP-Tg mice ( (Fig. 1a) . There was no significant difference between the amount of mtDNA in the tails of the wild-type mice and those of mtGFP-Tg mice that expressed mitochondrial-targeted EGFP (data not shown) [24] , suggesting that the increase in mtDNA in the Tfam/EGFP-Tg mice was due to the effect of the Tfam over-expression.
Analysis of mitochondrial disease symptoms in Tfam/EGFP over-expressing mito-mice
To investigate whether over-expression of Tfam improves the mitochondrial disease phenotypes, Tfam/EGFP over-expressing mito-mice (Tg-mito-mice) were generated by in vitro fertilization. Then the amounts of mtDNA in tail were estimated and we found that the Tg-mito-mice possessed 1.74 times as many as the average copy number of mtDNAs in their littermate mito-mice (Fig. 1b) .
Among several littermates of Tg-mito-mice and mito-mice, the mice with more than 50% #mtDNA were examined for their survival. Compared with mito-mice, the life spans of the Tg-mito-mice were significantly extended (P=0.01 in Mantel-Cox test), and the median survival periods were 54% prolonged, from 247 days in the mito-mice to 381 days in the Tg-mito-mice ( Fig. 2a ).
Because most mito-mice show a high concentration of blood urea nitrogen (BUN) (reflecting renal dysfunction) and ultimately die due to renal failure [7] , we measured the level of BUN in the mito-mice and Tg-mito-mice at eight months of age (Fig. 2b ).
An increased concentration of BUN was observed only in the mito-mice with more than 65% #mtDNA in the tail, which was consistent with previous reports [7, 23] . In the Tg-mito-mice group, the increase in BUN concentration was remarkably suppressed.
However, there was one exception. A mito-mouse with 75.5% #mtDNA had a normal BUN concentration, and it had a 1.58 times as much mtDNA copy number as the average of the control mito-mice at four weeks of age. These results indicate that the increased mtDNA copy number resulted in the recovery of kidney function. The kidneys of mito-mice with more than 80% #mtDNA showed ischemia and increased size with a granulated surface [7] . In contrast, the Tg-mito-mouse kidney with 89% #mtDNA, which contained 2.99 times as many mtDNA copies compared to the mito-mouse control kidney, showed a mild enlargement with a normal surface ( Fig. 2c; left panel). A histological analysis showed dilatation of the cortical proximal and distal tubules in the renal tissues of the mito-mouse, which was recovered in the Tg-mito-mouse ( Fig. 2c ; right panels).
Histochemical analyses of cytochrome c oxidase
Histochemical staining was used to evaluate the COX activity in the kidney ( Fig.   3a ) and heart (Fig. 3b) . The kidneys of mito-mice with 83% #mtDNA showed dilation in the cortical proximal and distal tubules and a reduction of COX activity with a compensatory up-regulation of SDH activity [25] . The kidneys of the Tg-mito-mice with 89% #mtDNA, however, had recovered both the COX activity and the histological characteristics of these tissues.
To confirm the effect of TFAM over-expression on the recovery of the mitochondrial activity in a single cell, cardiac muscle samples from the mito-mice and Tg-mito-mice (78% and 77%, respectively, &mtDNA in the heart tissue block) were subjected to histochemical and quantitative single-fiber PCR analyses. Serial sections were used to compare the COX activity and proportion of #mtDNA in a single muscle fiber. Consistent with a previous study [7] , we found that there were fibers with variable proportions of #mtDNA in the mito-mouse heart and that COX-positive fibers exhibited less than 85% #mtDNA. In contrast, there were COX-positive fibers with more than 85% &mtDNA in the Tg-mito-mouse heart (Fig. 3c) . Although it is difficult to estimate the amount of mtDNA in single fibers because there is no effective internal control, the elevation of the threshold percentage of the #mtDNA for maintaining COX activity was likely caused by the increase of mtDNA (2.27-fold higher than the mito-mouse control) due to the over-expression of TFAM.
The expression of mitochondrial tRNA was increased in Tg-mito-mice
In cells with #mtDNA, the amounts of mtDNA-coded proteins concurrently decreased regardless if the gene position was in the deleted region. The decrease in mtDNA-coded proteins should be due to the shortage of tRNAs [9] , and compensation for this shortage was thought to be responsible for prolongation of life span (Fig. 2a) , improved kidney function (Fig. 2b, c) and COX activity (Fig. 3a, b) in Tg-mito-mice.
Therefore, we examined the amount of tRNA Ser(AGY) that coded in the deleted region.
Compared with mito-mouse tissues, the amounts of tRNA Ser(AGY) were increased as follows: 1.56-fold in the heart of the Tg-mito-mouse (78% #mtDNA), which contained 2.27 times as many mtDNA copies as that of the mito-mouse (77%); 1.52-fold in the kidney of the Tg-mito-mouse (89%) which contained 2.99 times as many mtDNAs as that of the mito-mouse (83%); 2.42-fold in the soleus of the Tg-mito-mouse (70%) which contained 2.01 times as many mtDNAs as that of the mito-mouse (89%) (Fig. 4) .
The comparable result was observed using an additional set of mice (Fig. S2) . These results showed that the amount of tRNA was moderately restored in the Tg-mito-mouse,
Discussion
In this study we showed that Tfam over-expression improved the symptoms caused by mitochondrial deficiency with large deleted mtDNA. To elucidate the mechanism of this improvement, we created a new model for the pathogenicity of mutant mtDNA.
The accumulation of #mtDNA causes the simultaneous decrease of wild-type mtDNA, and a reduction in the tRNA supply. Consequently, the total protein levels of the respiratory complexes decrease as previously reported using cybrids with various proportions of #mtDNA [7] . A certain level of respiratory complexes is required to maintain normal activity, so a loss of mitochondrial function occurs when the wild-type mtDNA decreases below the threshold. When the copy number of the wild-type mtDNA increases under the sufficient condition of gene expression, the tRNA supply and protein synthesis should increase, resulting in the improvement of mitochondrial function.
It has been recognized commonly that the proportion of pathogenic mutant mtDNA is responsible for the occurrence of mitochondrial dysfunction. However, our model
proposes that the amount of wild-type mtDNA is important to maintain the mitochondrial function irrespective of the proportion of mutant mtDNA. There was a strong correlation between the amount of wild-type mtDNA and the life spans of both mito-mice and Tg-mito-mice (Fig. S3) , indicating that the amount of wild-type mtDNA directly affects the life span of these mice.
However, there is a limitation for this therapeutic treatment. In mito-mice, #mtDNA increases age-dependently [20] , and mice born with a lower proportion of #mtDNA may develop the mitochondrial diseases within their life span. In
Tg-mito-mice, although the threshold percentage was elevated (Fig. 3c) by the increase in mtDNA levels, the mitochondrial dysfunction occurred when the proportion of #mtDNA exceeded the threshold level. Thus, the mice could not be completely recovered even though the occurrence of the disease phenotype was extensively delayed and the life span was elongated (Fig. 2a ).
Considering the model further, the mtDNA up-regulating factor does not need to be applied with a transgenic technique in the zygote. Viral vectors, gene guns or other undiscovered medicines might instead be used to increase the copy number of mtDNA.
Furthermore, the method of increasing mtDNA copy number would be used to improve mitochondrial dysfunction in adults. There are several reports in which the copy number of mtDNA has been increased using a non-transgenic approach. For instance, rats fed a high-fat diet and injected with heparin had increased levels of plasma free fatty acids and increased respiratory capacity, which is accompanied by an increase in the mtDNA copy number in skeletal muscle [26] . Raising the cytosolic Ca 2+ with caffeine results in the increased expression of the peroxisome proliferative-activated receptor " coactivator-1! (PGC-1!) gene [27] , which increases mitochondrial biogenesis by activating the expression of Tfam and the subunits of the respiratory chain.
It has also been reported that several cytokines, such as IL-1' and combinations of TNF! and IL-1!, stimulate PGC-1! activity through the activation of p38 MAPK, which is accompanied by increased mitochondrial gene expression and cellular respiration [28] . Pursuing the mechanisms underlying these phenomena may provide clues for the discovery of potent medicines for the treatment of mitochondrial diseases.
This is the first study to find that increase in the amount of total mtDNA rescues the impairment caused by pathogenic mtDNA, which is the cause of mitochondrial diseases.
The therapeutic treatment in this study may be applied to human mitochondrial diseases, such as CPEO and KSS, especially in cases where the causal mtDNA mutation is the common deletion in which the deleted region extends from the mt-Atp8 to the mt-Nd5
, which is the same as the #mtDNA in mito-mice. genes. The mito-mouse and the Tg-mito-mouse displayed 83% and 89% #mtDNA in the kidney, respectively (a), and 78% and 77% in the heart, respectively (b). The Tg-mito-mouse displayed 2.99 and 2.27 times as many mtDNA copies as the mito-mouse in the kidney and heart, respectively. Bar, 100 µm in kidney and 50 µm in heart. (c) The proportion of #mtDNA in a COX-positive single fiber of heart muscle. Figure S1 
Generation of transgenic mice
DNA fragments for transgenesis were removed by double digestion with SalI and StuI (Fig. 1a) . These fragments were separated by agarose gel electrophoresis from the cloning vector and then purified with a MonoFas DNA purification kit I (GL Science).
The purified DNA fragments were injected into the pronuclei of the fertilized mouse (B6) oocytes according to the standard procedure [2] . To identify the transgenic mice, genomic DNA were prepared from the tails using a Gentra Puregene Tissue kit (QIAGEN) and two sets of primer pairs, (A) 5#-GCT CTA GAG CCT CTG CTA ACC-3#, 5#-TGA ACA GCT CCT CGC CCT TGC TC-3# and (B) 5#-TGA GCA AAG ACC CCA ACG AGA AGC-3#, 5#-TTA GCC AGA AGT CAG ATG CTC AAG-3#, were synthesized to amplify the PCR fragments (258 and 248 bp) specific to the EGFP sequence [3] .
Preparation of total RNA from mice tissues
Tails (about 5-mm lengths), hearts, kidneys and skeletal muscle samples for RNA preparation were cut and immediately frozen in liquid nitrogen. The frozen samples were crushed and homogenized (SK-100, Tokken). Then, the total RNA was isolated using the ISOGEN (NIPPON GENE) or QIAeasy plus (QIAGEN) kits.
Real-time RT-PCR analysis of Tfam mRNA
A One
Step SYBR RT-PCR Kit (TaKaRa) and the following primer sets were used for real-time RT-PCR; Tfam: TaKaRa MA027412 (primer set 1), TaKaRa MA076007
(primer set 2) (the set was designed in the 3' UTR region of the Tfam sequence), Rps18:
TaKaRa 050364.
Preparation of the mitochondrial fraction
Sixty milligrams of fresh kidneys were used to prepare the cytosol and mitochondrial fraction. The samples were homogenized with Tissue-Ruptor (QIAGEN) for 10 seconds followed by a Qproteome Mitochondria Isolation Kit (QIAGEN) treatment.
Western blot analysis
Proteins from the tissue samples were separated by SDS-PAGE and transferred onto a PVDF membrane (GE Healthcare). After being blocked with 5% BSA in TBS for !-Actin or 0.5% skim milk for others, the membranes were incubated with a specific antibody (anti-GFP: MBL, anti-CO1 and anti-!-Actin: Abcam, anti-TIM23: BD).
Horseradish peroxidase-conjugated goat antibody to rabbit IgG (Bio-Rad) or mouse IgG (Abcam) was used as a secondary antibody. Immun-Star HRP Substrate (Bio-Rad) was used for the detection.
Immunogold electron microscopy
The 
DNA Binding Assay
DNA fragments that encode TFAM and TFAM/EGFP with a 6$His-tag at the C-terminus were generated and cloned into the vector pCAGGS. The recombinant proteins were expressed in COS7 cells and purified using the Ni-NTA Spin Kit 
